{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T04:36:42Z","timestamp":1713328602442},"reference-count":18,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["IJDVL"],"DOI":"10.25259\/ijdvl_612_2022","type":"journal-article","created":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T04:12:02Z","timestamp":1674879122000},"page":"589-591","update-policy":"http:\/\/dx.doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pembrolizumab-induced toxic epidermal necrolysis: A rare cause of severe adverse drug reaction"],"prefix":"10.25259","volume":"89","author":[{"given":"Shekhar","family":"Neema","sequence":"first","affiliation":[{"name":"Armed Forces Medical College, Pune, Maharashtra, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shashank","family":"Sathu","sequence":"additional","affiliation":[{"name":"Armed Forces Medical College, Pune, Maharashtra, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biju","family":"Vasudevan","sequence":"additional","affiliation":[{"name":"Armed Forces Medical College, Pune, Maharashtra, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surendra","family":"Shreshta","sequence":"additional","affiliation":[{"name":"Armed Forces Medical College, Pune, Maharashtra, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siddharth","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Armed Forces Medical College, Pune, Maharashtra, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lekshmipriya","family":"K","sequence":"additional","affiliation":[{"name":"Armed Forces Medical College, Pune, Maharashtra, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2023,1,25]]},"reference":[{"key":"10.25259\/IJDVL_612_2022\/ref-1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4103\/ijd.IJD_671_21","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: 11-year demographic clinical and prognostic characteristics","volume":"67","author":"Acar","year":"2022","journal-title":"Indian J Dermatol"},{"key":"10.25259\/IJDVL_612_2022\/ref-2","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.1158\/1078-0432.CCR-15-2872","article-title":"Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy","volume":"22","author":"Goldinger","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.25259\/IJDVL_612_2022\/ref-3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1001\/archderm.139.1.26","article-title":"Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: Multicenter retrospective analysis of 48 consecutive cases","volume":"139","author":"Prins","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.25259\/IJDVL_612_2022\/ref-4","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1007\/s00432-020-03458-6","article-title":"PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: A retrospective analysis from the University of Southern California","volume":"147","author":"In","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.25259\/IJDVL_612_2022\/ref-5","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.25259\/IJDVL_612_2022\/ref-6","doi-asserted-by":"publisher","first-page":"E183","DOI":"10.1111\/ijd.14811","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: A systematic review","volume":"59","author":"Maloney","year":"2020","journal-title":"Int J Dermatol"},{"key":"10.25259\/IJDVL_612_2022\/ref-7","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/DAD.0000000000001527","article-title":"Pembrolizumab-induced Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis in a patient with metastatic cervical squamous cell carcinoma: A case report","volume":"42","author":"Robinson","year":"2020","journal-title":"Am J Dermatopathol"},{"key":"10.25259\/IJDVL_612_2022\/ref-8","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2147\/CMAR.S163391","article-title":"Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies","volume":"10","author":"Chen","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.25259\/IJDVL_612_2022\/ref-9","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1177\/1078155219890659","article-title":"Toxic epidermal necrolysis associated with pembrolizumab","volume":"26","author":"Cai","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"10.25259\/IJDVL_612_2022\/ref-10","doi-asserted-by":"publisher","first-page":"omac025","DOI":"10.1093\/omcr\/omac025","article-title":"Pembrolizumab-induced toxic epidermal necrolysis: Case report","volume":"2022","author":"Chow","year":"2022","journal-title":"Oxf Med Case Reports"},{"key":"10.25259\/IJDVL_612_2022\/ref-11","doi-asserted-by":"publisher","first-page":"e738","DOI":"10.1097\/CAD.0000000000001162","article-title":"Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis","volume":"33","author":"Kian","year":"2022","journal-title":"Anticancer Drugs"},{"key":"10.25259\/IJDVL_612_2022\/ref-12","first-page":"34","article-title":"Pembrolizumab-induced toxic epidermal necrolysis in a patient with metastatic esophageal adenocarcinoma","volume":"105","author":"Gallo Marin","year":"2022","journal-title":"R I Med J (2013)"},{"key":"10.25259\/IJDVL_612_2022\/ref-13","doi-asserted-by":"publisher","first-page":"100048","DOI":"10.1016\/j.cpccr.2020.100048","article-title":"A case of Stevens-Johnson syndrome\/toxic epidermal necrolysis in a patient receiving chemo-immunotherapy with pemetrexed and pembrolizumab","volume":"3","author":"Storandt","year":"2021","journal-title":"CPC: Case Reports"},{"key":"10.25259\/IJDVL_612_2022\/ref-14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/cia2.12150","article-title":"Toxic epidermal necrolysis as a complication of pembrolizumab treatment in a lung cancer patient","volume":"4","author":"Aoyama","year":"2021","journal-title":"J Cutan Immunol Allerg"},{"key":"10.25259\/IJDVL_612_2022\/ref-15","first-page":"120","article-title":"A case of pembrolizumab-induced toxic epidermal necrolysis","volume":"60","author":"Choi","year":"2022","journal-title":"Korean J Dermatol"},{"key":"10.25259\/IJDVL_612_2022\/ref-16","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.21037\/tcr-21-470","article-title":"Pembrolizumab-induced autoimmune Stevens-Johnson syndrome\/toxic epidermal necrolysis with myositis and myocarditis in a patient with esophagogastric junction carcinoma: A case report","volume":"10","author":"Cao","year":"2021","journal-title":"Transl Cancer Res"},{"key":"10.25259\/IJDVL_612_2022\/ref-17","doi-asserted-by":"publisher","first-page":"23247096211037462","DOI":"10.1177\/23247096211037462","article-title":"A case of Guillain-Barr\u00e9 syndrome and Stevens-Johnson syndrome\/toxic epidermal necrosis overlap after pembrolizumab treatment","volume":"9","author":"Oguri","year":"2021","journal-title":"J Investig Med High Impact Case Rep"},{"key":"10.25259\/IJDVL_612_2022\/ref-18","doi-asserted-by":"publisher","first-page":"100478","DOI":"10.1016\/j.currproblcancer.2019.05.001","article-title":"Pembrolizumab induced toxic epidermal necrolysis","volume":"44","author":"Kumar","year":"2020","journal-title":"Curr Probl Cancer"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/pembrolizumab-induced-toxic-epidermal-necrolysis-a-rare-cause-of-severe-adverse-drug-reaction\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/pembrolizumab-induced-toxic-epidermal-necrolysis-a-rare-cause-of-severe-adverse-drug-reaction\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T08:47:36Z","timestamp":1686991656000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/pembrolizumab-induced-toxic-epidermal-necrolysis-a-rare-cause-of-severe-adverse-drug-reaction\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,25]]},"references-count":18,"alternative-id":["10.25259\/IJDVL_612_2022"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_612_2022","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,25]]},"article-number":"589"}}